[1]陈嘉怡 张芳婷 许昌 许卫卫.英国生物样本库公众参与实践模式对提高我国临床研究质量的启示[J].中国卫生质量管理,2025,32(06):105-109.[doi:10.13912/j.cnki.chqm.2025.32.6.20]
　CHEN Jiayi,ZHANG Fangting,XU Chang.The Implications of the UK Biobank’s Public Participation Practice Model for Improving the Quality of Clinical Research in China[J].Chinese Health Quality Management,2025,32(06):105-109.[doi:10.13912/j.cnki.chqm.2025.32.6.20]
点击复制

英国生物样本库公众参与实践模式对提高我国临床研究质量的启示()
分享到：

《中国卫生质量管理》[ISSN:1006-7515/CN:CN 61-1283/R]

卷:
第32卷
期数:
2025年06期
页码:
105-109
栏目:
问题与探索
出版日期:
2025-06-15

文章信息/Info

Title:
The Implications of the UK Biobank’s Public Participation Practice Model for Improving the Quality of Clinical Research in China
作者:
陈嘉怡 张芳婷 许昌 许卫卫
北京大学深圳医院
Author(s):
CHEN Jiayi;  ZHANG Fangting;  XU Chang
Peking University Shenzhen Hospital
关键词:
生物样本库; 研究参与者; 知情同意; 公众参与; 临床研究质量
Keywords:
Biobank; Research Participants;  Informed Consent;  Public Participation; Clinical Research Quality
分类号:
R197.1
DOI:
10.13912/j.cnki.chqm.2025.32.6.20
文献标志码:
A
摘要:
大样本人群研究对医学发展和人类健康至关重要。临床研究依赖人体样本数据，其来源、质量、数量是生物医学研究的基础。本研究梳理我国公众参与临床研究的影响因素，借鉴英国生物样本库的公众参与实践模式，从知情同意、出入库管理、匿名化处理、退出和信息公开机制等方面，介绍样本医院生物样本库智慧化管理经验，为提高我国临床研究质量提出建议。
Abstract:
Large-scale population studies are of paramount importance for medical advancement and human health. Clinical research relies on human sample data, with its origin, quality, and quantity forming the foundation of high-quality biomedical research.This study sorts out the influencing factors of the public’s participation in clinical research in China, drawing lessons from the public participation practice model of the UK Biobank,introduces intelligent management experience of biobank in the sample hospital, covering aspects such as informed consent, inbound and outbound management, anonymization, withdrawal and information disclosure mechanisms. It proposes suggestions for improving the quality of clinical research in China.

参考文献/References:

［1］国家卫生健康委，教育部，科技部，等.涉及人的生命科学和医学研究伦理审查办法：国卫科教发〔2023〕4号［EB/OL］.(2023-02-18)［2024-03-20］.http: //www.nhc.gov.cn/qjjys/s7946/202302/c337 4c180dc5489d85f95df5b46afaf5.shtml.［2］MCCOY MS, WARSH J, RAND L,et al.Patient and public involvement: two sides of the same coin or different coins altogether?［J］.Bioethics,2019,33(6): 708-715.［3］杨辉,SHANE THOMAS,COLETTE BROWNING. 公众参与医疗服务质量改进:国际经验和中国展望［J］. 中国卫生质量管理,2010,17(2):108-112.［4］MOULT A, BAKER D, ARIES A,et al.Using the UK standards for public involvement to evaluate the public involvement sections of annual reports from NIHR managed research centres［J］.Research Involvement and Engagement，2023,9（1）: 109.［5］吉萍,褚红玲. 英国公众与患者参与医学研究的实践［J］. 医学与哲学,2020,41(20):78-80.［6］王晶. 临床研究利益冲突管理的构建及运行［J］. 中国医院,2022,26(11):57-59. ［7］汪旻晖,赵杨,王陵,等. 真实世界研究中个人信息和隐私保护的考虑要点［J］. 中国新药杂志,2022,31(16):1565-1570.［8］彭运朋,徐毅华. 医疗人工智能对知情同意的挑战与应对［J］. 医学与哲学,2023,44(10):25-29.［9］蔡雨廷,徐玉梅. 科技伦理治理对构建和谐医患关系的作用研究［J］. 中国医学伦理学,2023,36(9):1012-1016.［10］李旭,王妍,刘玉秀,等. 生物样本泛知情同意的撤回权及相关问题探讨［J］. 医学与哲学,2023,44(10):16-18.［11］李毅静,蒋艳. 基于患者体验的护理提升行动与思考［J］. 中国卫生质量管理,2024,31(4):63-67.［12］YUSOF MYPM, TEC CH, NG CJ. Electronic informed consent criteria for research ethics review: a scoping review［J］. BMC Medical Ethics, 2022, 23(1):117.［13］潘睿,左祥林,刘小林,等. 临床试验生物样本管理的现状与挑战［J］.中国医学伦理学,2023,36(6):606-612.［14］ELLIOTT P, PEAKMAN TC.The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine［J］.Int J Epidemiol,2008,37(2):234-244.［15］CONROY MC,LACEY B,BEEVI J,et al.UK Biobank: a globally important resource for cancer research［J］.British Journal of Cancer,2023,128(4): 519-527.［16］UK Biobank.World’s largest genetic project opens the door to new era for treatments and cures: UK Biobank’s major milestone［EB/OL］.(2023-11-30)［2024-06-06］.https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/news/world-s-largest-genetic-project-opens-the-door-to-new-era-for-treatments-and-cures-uk-biobank-s-major-milestone.［17］UK Biobank.North West - Haydock Research Ethics Committee Attendance at Committee meeting on 08 June 2021［EB/OL］.(2021-06-18)［2024-06-06］.https://www.ukbiobank.ac.uk/media/p4yjfqcp/2021-nwrec-rtb-application-and-approval.pdf.［18］复旦大学，生物芯片上海国家工程研究中心，上海芯超生物科技有限公司,等.人类生物样本保藏伦理要求［EB/OL］. (2020-04-28)［2024-03-20］. https://std.samr.gov.cn/gb/search/gbDetailed?id=A47A713B 765014ABE05397BE0A0ABB25.［19］UK Biobank.UK Biobank ethics and governance framework［EB/OL］.(2007-10-01)［2024-03-20］.www.ukbiobank.ac.uk/media/0xsbmfmw/egf.pdf.［20］尹忠楠,杨小雪,张春竹,等. 临床生物样本库管理系统建设与应用［J］. 中国医药生物技术,2023,18(5):471-475. ［21］中华人民共和国国务院令.中华人民共和国人类遗传资源管理条例［EB/OL］. (2019-05-28)［2024-03-20］.https://www.gov.cn/gongbao/content/2019/content_5404150.htm.［22］科学技术部令.人类遗传资源管理条例实施细则［EB/OL］. (2023-05-26)［2024-03-20］.https://www.safea.gov.cn/xxgk/xinxifenlei/fdzdgknr/fgzc/bmgz/20 2306/t20230601_186416.html.［23］CHANDRASHEKAR C, SHETTY SS, RADHAKRISHNAN R.Evolution of biobanks and ethical governance for the emerging applications in biomedical research［J］.J Oral Maxillofac Pathol,2022,26(4):433-439.［24］全国人民代表大会常务委员会.中华人民共和国个人信息保护法［EB/OL］.(2021-08-20）［2024-03-20］.https://www.gov.cn/xinwen/2021- 08/20/content_5632486.htm.［25］全国人民代表大会常务委员会.中华人民共和国数据安全法［EB/OL］.(2021-06-11）［2024-03-20］.https://www.gov.cn/xinwen/2021- 06/11/content_5616919.htm.［26］栗召辉,温颖,祁军. 生物样本库建设的发展状况与分析［J］. 口岸卫生控制,2024,29(1):23-27. ［27］张育军,叶磊,高芳芳,等. 生物样本库建设是临床医学研究的基石［J］. 转化医学杂志,2014,3(6):347-351,355. ［28］高莹,杨建,王舒. 生物样本库的发展现状［J］. 转化医学杂志,2015,4(6):329-331. ［29］芦慧敏,王岩,陈聪,等. 生物样本库信息管理系统的建设与应用［J］. 重庆医学,2023,52(14):2211-2214.［30］杨梦婕,周吉银. 临床研究结果发布的伦理审查辨析［J］. 医学与哲学,2023,44(24):24-27.

更新日期/Last Update: 2025-06-15